Navigation Links
Alzheimer's Therapeutics Reviewed by NeuroPerspective
Date:9/6/2012

CARDIFF, Calif., Sept. 6, 2012 /PRNewswire/ -- NI Research has released the September issue of NeuroPerspective, which features a comprehensive review of Alzheimer's therapeutics. The focus is particularly timely, given the recent release of Phase III results for bapineuzumab and solaneuzumab, which serve as a reminder of how poorly the pharma industry has allocated its resources to date, both in terms of the premature embrace of the amyloid model, and the rush into hugely expensive Phase III programs without obtaining Phase II justification.

This 46-page issue is the largest and most comprehensive issue of NeuroPerspective ever produced, and includes:

1) An overview of the biology of Alzheimer's as it is currently conceptualized, albeit not yet validated.
2) A review of the many therapeutic strategies that have been employed, and that are currently under development.
3) The companies and programs that are in clinical, preclinical, and discovery stage. Over 215 therapeutic programs are covered in this review. They include variations on the secretase theme from Bristol Myers Squibb, EnVivo Pharmaceuticals, and Neurogenetic Pharmaceuticals; innovative approaches to disease progression from Merck/Alectos, Roche/reMYND, and NeuroPhage; and those with clinical data, such as EnVivo, Lundbeck, TauRx, and Prana.  
4) What is and is not clear from the sparse solanezumab results thus far disclosed, which have served as a Rorschach for those looking to have their preconceptions supported. With all due respect to the fever dreams of some Street analysts, these results are not going to be the basis for filing a NDA.
5) A sampling of novel biomarkers in development for AD, aimed at identifying markers for MCI/prodromal AD that will permit early intervention.
6) A spotlight review of AC Immune, one of the leaders in the development of antibodies for both amyloid and tau.
7) The positive results for EnVivo Pharma's EVP-6124, and the potential for alternate mechanistic approaches to effectively address Alzheimer's.

Other topics covered in NP September:
8) Reading between the line regarding Naurex's rapid-acting antidepressant, the most important neuropsychiatric development of the year.
9) 'Elan 1969-2013:' Ramifications of Elan's decision to spin-out Neotope Bioscience.
10) The status of Merck Serono's restructuring and the implications for its CNS programming.
11) News and developments from Cortex Pharmaceuticals, NeuroSearch, and more.

NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. NeuroPerspective (formerly NeuroInvestment) is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development.

A one-year subscription to NeuroPerspective is $2,300. The September issue of NeuroPerspective is available for $400 as a single-issue purchase.

NI Research also publishes NeuroLicensing, the Private CNS Company Review, and has just launched NeuroSynopsis, a monthly four-page summary of the most important highlights from NeuroPerspective. NIR also provides consulting services to the pharma industry.

Further information and online purchasing with immediate delivery are available at http://www.niresearch.com/onlinestore.html


'/>"/>
SOURCE NI Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
2. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
3. Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
4. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
5. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
6. Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team
7. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
8. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
9. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
10. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
11. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Bacterial biofilms, surface adherent communities of bacteria that ... ranging from food poisoning and catheter infections to gum disease and the rejection of ... billions of dollars per year, there is currently a paucity of means for preventing ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... manufacturers to re-engineer their control technology again and again. METTLER TOLEDO has released ... machine manufacturers. The videos illustrate how integration of the ACT350 into Siemens and ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... other leaders of the Maryland Biohealth community in developing and issuing recommendations to ... 3 U.S. BioHealth Innovation Hub by 2023. , The recommendations ...
(Date:5/21/2017)... CA (PRWEB) , ... May 19, 2017 , ... ... annual meeting and educational conference of the American Association of Bioanalysts (AAB) and ... Galleria Hotel in Houston. The conference reinforces AAB’s commitment to excellence in clinical ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
Breaking Biology News(10 mins):